RxDoctor Payments Data

Shagufta Chowhan, MD

Psychiatry · South Bend, INNPI 1881669695

Payments from drug & device makers

$1,517in general payments, 2019–2025

Across 40 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$394
  • Teva Pharmaceuticals USA, Inc.$231
  • AbbVie$224
  • Otsuka America Pharmaceutical, Inc.$175
  • Corium, LLC$113
  • E.r. Squibb & Sons, L.L.C.$88
  • plus $291 from 8 others

What the payments were for

  • Food & beverage$1,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,517 in reported general payments places this provider in the 70th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$41,974
Medicare patients
98
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate240$780,798
AustedoDeutetrabenazine14$89,273
RexultiBrexpiprazole35$50,046
SecuadoAsenapine21$31,133
Risperdal ConstaRisperidone Microspheres12$30,471
Divalproex Sodium ErDivalproex Sodium319$19,697
VraylarCariprazine Hcl13$19,351
Quetiapine Fumarate529$15,537
QuviviqDaridorexant Hcl24$11,894
Olanzapine173$9,064
Doxepin Hcl41$8,871
Clozapine66$8,581
Paliperidone ErPaliperidone43$8,477
Ziprasidone Hcl70$7,705
Sertraline Hcl384$5,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$18$811,269252 claims
Teva Pharmaceuticals USA, Inc.Austedo$231$89,27314 claims
Otsuka America Pharmaceutical, Inc.Rexulti$175$50,04635 claims
AbbVieVraylar$224$19,35113 claims
Almatica Pharma LLCSertraline Hcl$26$5,426384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →